Abstracts tagged "leukocytes and nephritis"

Abstract Number: 2659 • 2017 ACR/ARHP Annual Meeting
Development of a Protocol for Single Cell Transcriptomics of Cells from Cryopreserved Lupus Nephritis Kidney Tissue and Urine for the Accelerating Medicines Partnership RA/SLE Network
Deepak Rao¹, Celine C. Berthier², Arnon Arazi³, Anne Davidson⁴, Yanyan Liu⁵, Edward Browne³, Thomas Eisenhaure³, Adam Chicoine⁶, David Lieb³, Dawn Smilek⁷, Patti Tosta⁷, James Lederer⁸, Michael Brenner⁵, David Hildeman⁹, E. Steve Woodle¹⁰, David Wofsy¹¹, Jennifer H. Anolik¹², Matthias Kretzler¹³, Nir Hacohen¹⁴ and Betty Diamond¹⁵, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ³Broad Institute, Cambridge, MA, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Immune Tolerance Network, San Francisco, CA, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹University of Cincinnati, Cincinnati, OH, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Rheumatology, UCSF, San Francisco, CA, ¹²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹³Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ¹⁴Harvard Medical School, Boston, MA, ¹⁵Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: There is a critical need to define the cells that mediate tissue damage in lupus nephritis. Here we aimed to establish a protocol to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].